Clal Biotechnology Industries’ (CBI’s) portfolio of investments continues to progress on multiple fronts. Most importantly, MediWound (CBI owns a 35% stake) announced in March that it had been approached by a third party to consummate a strategic transaction. The exact nature of the proposed transaction is unclear and could range from a product out-licensing to the acquisition of all of MediWound. The companies are in advanced discussions and conducting mutual due diligence.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs